The multiple sclerosis is an autoimmune disease that affects the central nervous system and is the most common cause of neurological disability in young adults. The immune system, especially lymphocytes, destroys the myelin sheath that surrounds and protects parts of neurons. This “demyelination” then disrupts the transmission of nerve impulses.
An antibody that limits the destruction of the myelin sheath by lymphocytes
Current treatments reduce disease flare-ups but do not yet succeed in halting its progress. As part of their research on multiple sclerosis, Inserm researchers from Prof. Denis Vivien’s unit have succeeded in developing an antibody with potential therapeutic effects against the disease. This antibody (Glunomab) has been tested on mice. It prevents the opening of the blood-brain barrier, thus limiting the passage of lymphocytes.
“Following intravenous injection of Glunomab, the progression of motor disturbances in mice was blocked. In treated mice, this effect was associated with decreased infiltration of lymphocytes into nervous tissue and reduced demyelination.” explain the researchers who suggest that this strategy could represent a promising therapy to fight against multiple sclerosis.
Inserm has filed a patent application as part of a collaboration with a healthcare industry.
Read also :
Multiple sclerosis: soon a treatment?
Multiple sclerosis: vitamin D deficiency doubles the risk
